Showing 1201-1210 of 1603 results for "".
- New to SENTE BOD: Clint Carnell and Clement Gingrashttps://practicaldermatology.com/news/new-to-sente-bod-clint-carnell-and-clement-gingras/2460093/SENTÉ has appointed Clint Carnell and Clement Gingras to its Board of Directors effective immediately. "We are thrilled to have both Clint and Clement join the SENTÉ team," says Faheem Hasnain, Chairman of t
- AbbVie to Acquire Allerganhttps://practicaldermatology.com/news/abbvie-to-acquire-allergan/2460076/AbbVie Inc. and Allergan plc have entered into a definitive transaction agreement under which AbbVie will acquire Al
- L’Oréal Rewards Social Initiatives Led By Dermatologists at WCDhttps://practicaldermatology.com/news/loreal-rewards-social-initiatives-led-by-dermatologists-at-wcd/2460073/In partnership with the International League of Dermatological Societies (ILDS) and the 24th World Congress of Dermatology (WCD), L’Oréal announced the laureates of the third International Awards for Social Responsibility in Dermatology: “Caring to Inspire Skin Conf
- Sonrei Sea Clearly Gel Sunscreens Launchhttps://practicaldermatology.com/news/sonrei-sea-clearly-gel-sunscreens-launch/2460070/A new eco-friendly, gel-based sunscreen line from Sonrei, LLC is now available. “Crafted for every kind,” Sonrei is driven by a commitment of bringing to market a translucent broad-spectrum SPF with environmental principles at the core, the company says. Sonrei Sea Clearly T
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en
- Study: Indoor Tanning Addiction May Be Abetted by Genetic and Psychiatric Factorshttps://practicaldermatology.com/news/study-indoor-tanning-addiction-may-be-abetted-by-genetic-and-psychiatric-factors/2460059/A combination of elevated symptoms of depression along with modifications in a gene responsible for dopamine activity appear to influence an addiction to indoor tanning in young, white non-Hispanic women, a new study suggests. The findings appear in the Annals of Behaviora
- Water's Edge Dermatology Acquires Coast Dermatologyhttps://practicaldermatology.com/news/waters-edge-dermatology-acquires-coast-dermatology/2460055/Water's Edge Dermatology, a provider of comprehensive dermatology services through 37 Florida locations, has acquired a controlling interest in Coast Dermatology, a medical/cosmetic dermatology practice in Venice, Florida. Terms of the transaction were not disclosed. This transactio
- Soliton Takes On Cellulitehttps://practicaldermatology.com/news/soliton-takes-on-cellulite-2/2460049/Soliton, Inc.’s Rapid Acoustic Pulse ("RAP") device may selectively disrupt of the fibrotic septa that contribute to the appearance of cellulite, according to preclinical studies. The device is cleated for use in tattoo removal, howe
- Constellation Alpha Capital Corp. to Merge with DermTech, Inc.https://practicaldermatology.com/news/constellation-alpha-capital-corp-to-merge-with-dermtech-inc/2460041/Constellation Alpha Capital Corp. is merging with DermTech, Inc., a molecular genomics company with an initial focus on skin cancer. "DermTech has developed a deep pipeline of dermatology-focused dia
- National Emsculpt Week Kicks Offhttps://practicaldermatology.com/news/national-emsculpt-week-kicks-off/2460033/BTL has proclaimed the week of May 20 "National Emsculpt Week," in honor of the first and only non-invasive treatment to go beyond the elimination of fat cells to strengthen and define muscles. National Emsculpt Week was just registered with the National Day Calendar organization,